Valeant Debacle is Bad News for Ackman, Ubben, Others

The healthcare stock fell so far on Wednesday that trading was briefly halted. But some hedge fund die-hards say the bloodbath is a buying opportunity.

Stephen Taub October 22, 2015

Michael Pearson, Valeant Pharmaceuticals International (Bloomberg) This Valeant Pharmaceuticals International sell-off is starting to get ugly. Shares of the fast-growing, acquisitive drug peddler plummeted another 19 percent Wednesday — after briefly falling as much as

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.03 build:2025-12-12 Login